Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2012

Huang Fei, Xu Li-An, Khambata-Ford Shirin

Abstract excerpt

PURPOSE: This study examined potential correlations between markers related to the insulin-like growth factor-1 receptor (IGF-1R) pathway and clinical benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN: Gene expression profiles for 70 pretreatment specimens from metastatic lesions of patients with chemorefractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Insulin-Like Growth Factor Binding Protein 3

Share to Insulin-Like Growth Factor I

Share to Neoplasm Metastasis

Share to ras Proteins

Share to Receptor, IGF Type 1

Share to Receptor, Insulin

Source

Identifiers

PMID: 22294722
DOI: 10.1158/1078-0432.CCR-11-1135

Genes

EGFR
INSR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.PMID 22294722Read ↗

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.Semantic proximity Read ↗

Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.Semantic proximity Read ↗

Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.Semantic proximity Read ↗

Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression ProfilingSemantic proximity Read ↗

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.Semantic proximity Read ↗

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Semantic proximity Read ↗

Drugging IGF-1R in cancer: New insights and emerging opportunitiesSemantic proximity Read ↗

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.Semantic proximity Read ↗

Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.Semantic proximity Read ↗

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.